- Knowledge Base
- Latest News
- July 2020
-
Latest News
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- September 2023
- August 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- February 2019
- January 2019
- November 2018
- June 2018
- January 2018
- November 2017
-
Product Help and Guides
- Coronavirus Help Centre
- Vision 3 Release Guides
- Consultation Manager
- Vision +
- SIS Vision+ Release Guides
- Registration
- Patient Services - England, Scotland and Northern Ireland
- My Health Online (MHOL) - Wales only
- Vision 3 Appointments
- Daybook
- Search and Reports
- Clinical Audit
- Mail Manager
- Management Tools
- Registration Links
- GP Communicator
- Utilities
- Outcomes Manager
- Vision Anywhere
- Vision Anywhere - Release Guides
- Appointments
- Appointments Setup
- Appointments Reporting
- Tasks
- Vision360 Releases
- Shared Care
- Community
- General Hints and Tips
- Scotland Only
- EMIS vs Cegedim - Key Comparisons
- England Only
- Wales Only
- Northern Ireland Only
- Medication Dictionary Releases
- Partner Solutions
- Seasonal Influenza Help Centre
- Patient Groups
- Flash Cards - Short Printable 'How do I..? Guides
- Known Issues
- Desk Aids
-
Webinars and Events
-
Training and Support
-
Downloads
-
vStore and Partners
Co-prescribing of Carbamazepine and Diltiazem
Vision has been made aware of an incident in relation to the hospitalisation of a patient as a result of Carbamazepine toxicity caused by an interaction between Carbamazepine and Diltiazem that were co-administered to the patient.
A clinical safety report has been issued by NHS National Services Scotland to Vision advising that the severity of this interaction is categorised as minor within the Vision GP clinical system, whereas the BNF categorises the interaction as severe (which corresponds to a Vision categorisation of major). As a consequence of the Vision categorisation of minor, the interaction warning for these drugs was not viewed by the prescriber and no corrective action was taken on co-prescribing to the patient who was hospitalised.
Currently, the following is the Vision drug interaction warning for concomitant prescribing of Tildiem (Diltiazem) with Tegretol (Carbamazepine):
Vision has reviewed the severity of this interaction warning and will been updated from ‘Minor’ to ‘Major’ in an upcoming drug dictionary update.
In the meantime, Vision are advising GP practices to exercise both caution and monitoring when prescribing Carbamazepine and Diltiazem simultaneously to try and prevent future patient harm. Prescribers should be vigilant when co-prescribing these drugs in view of the risk of a significant increase in Carbamazepine levels leading to Carbamazepine toxicity due Diltiazem affecting drug metabolism.
As additional mitigation, this will also be highlighted to all Superintendent Pharmacists.
An audit has been made available in Vision+ for use to identify patients co-prescribed these drugs. The name of the pathway is “Carbamazepine and Diltiazem co-prescribing audit” and the reporting lines are as follows:
This audit will be helpful where a practice may wish to undertake a review of patients co-prescribed these drugs, and consider if any drug level monitoring and/or drug dosage adjustments are required.